Novo-Nordisk, DK0062498333

Novo Nordisk stock gets EU approval for FREHEMGO hemophilia drug

Published on 11/16/2026 at 11:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk stock gets a new regulatory milestone as the EU approves FREHEMGO for hemophilia A. The therapy offers three dosing schedules.

EU approval expands Novo's hemophilia portfolio

  • Novo Nordisk said FREHEMGO was approved in the European Union for hemophilia A on November 13.
  • The treatment offers monthly, every-two-weeks or weekly dosing options.
  • The approval adds a regulatory milestone beyond Novo Nordisk's obesity and diabetes franchises.
Novo-Nordisk, DK0062498333, Illustration mit AI erstellt.

On November 13, Novo Nordisk said in its Novo Nordisk newsroom that FREHEMGO, or denecimig, had been approved in the European Union for hemophilia A. The authorization covers monthly, every-two-weeks and weekly dosing options.

The decision gives Novo Nordisk a new regulatory milestone in rare blood disorders as the company continues to manage a portfolio spanning hemophilia, diabetes and obesity care. The dosing choice is a central feature of the approval because it may allow treatment schedules to be matched more closely with patient and physician preferences.

A broader specialty-care portfolio

FREHEMGO is intended for people with hemophilia A, a bleeding disorder in which the body lacks sufficient factor VIII activity for normal blood clotting. Novo Nordisk has not presented the European approval as a change to its near-term obesity strategy, but the decision adds another approved medicine to the group's specialty-care offering.

For investors, the approval is relevant primarily as a portfolio and pipeline milestone. Its commercial contribution will depend on the treatment's rollout, physician adoption and reimbursement conditions across European markets. The flexible dosing schedule could support differentiation in a field where convenience and treatment burden influence long-term use.

Novo Nordisk stock traded at 38.53 euros on Lang & Schwarz at 11:39 CET on Monday, November 16, 2026.

Novo Nordisk A/S

  • Company: Novo Nordisk A/S
  • ISIN: DK0062498333
  • Latest quote: 38.53 euros on Lang & Schwarz, Monday, November 16, 2026, at 11:39 CET
  • Regulatory milestone: European Union approval for FREHEMGO in hemophilia A

Broader market developments are covered in Current market reports.

More news and analyses on Novo Nordisk stock

Disclaimer...
en | DK0062498333 | NOVO-NORDISK | boerse | 70520406 | bgmi